(Q35618929)

9 August 2017

1 reference

title

Current concepts in the prevention of Alzheimer's disease (English)

1 reference

9 August 2017

0 references

Mary Sano

1

1 reference

9 August 2017

publication date

1 November 2003

1 reference

9 August 2017

1 reference

9 August 2017

volume

8

1 reference

9 August 2017

issue

11

1 reference

9 August 2017

page(s)

846-853

1 reference

Double placebo design in a prevention trial for Alzheimer's disease.

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

Effect of postmenopausal hormone therapy on cognitive function: the Heart and Estrogen/progestin Replacement Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

Hormone replacement therapy and cognition: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

Estrogen therapy in postmenopausal women: effects on cognitive function and dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

Ovariectomy and 17beta-estradiol modulate the levels of Alzheimer's amyloid beta peptides in brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

Generation of Alzheimer beta-amyloid protein in the trans-Golgi network in the apparent absence of vesicle formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

Plasma total homocysteine and cognitive performance in a volunteer elderly population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

Estrogen receptors colocalize with low-affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

Plasma homocysteine as a risk factor for dementia and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

Dementia-free life expectancy (DemFLE) in The Netherlands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

Identification of cognitive impairment in the elderly: homocysteine is an early marker

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson's disease. Parkinson Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

Statins and the risk of dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

The neurology of mitochondrial DNA disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

Dietary intake of antioxidants and risk of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

Risk of Alzheimer's disease and duration of NSAID use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

Estrogen to treat Alzheimer's disease: too little, too late? So what's a woman to do?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

Nonsteroidal anti-inflammatory drugs in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

Prevention of Alzheimer's disease: where we stand

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

Mechanisms to prevent the toxicity of chronic neuroinflammation on forebrain cholinergic neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

Alzheimer's disease-do tauists and baptists finally shake hands?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

Clinical trial of indomethacin in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

Estimating the costs of informal care for people with Alzheimer's disease: methodological and practical challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

Inflammatory mechanisms in Alzheimer's disease: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

A Pilot Study of Vitamins to Lower Plasma Homocysteine Levels in Alzheimer Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

Total serum homocysteine in senile dementia of Alzheimer type

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

7 January 2021

Homocysteine and cognitive function in the Sacramento Area Latino Study on Aging

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

7 January 2021

Is metabolic evidence for vitamin B-12 and folate deficiency more frequent in elderly patients with Alzheimer's disease?

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

7 January 2021

Antioxidative activity of ginkgolides against superoxide in an aprotic environment

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

7 January 2021

Gonadal steroids regulate dendritic spine density in hippocampal pyramidal cells in adulthood

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

7 January 2021

Effect of long-term treatment with EGb 761 on age-dependent structural changes in the hippocampi of three inbred mouse strains.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

7 January 2021

Do dietary antioxidants prevent Alzheimer's disease?

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019283

7 January 2021

10.1017/S1092852900019283

Identifiers

DOI

1 reference

9 August 2017

1 reference